KDCA National Institute of Health and Moderna "Mutual Cooperation on COVID-19 and mRNA Vaccine Research"

[Image source=Yonhap News]

[Asia Economy Reporter Seo So-jeong] The Korea Disease Control and Prevention Agency’s National Institute of Health (Director Kwon Jun-wook) and Moderna (CEO St?phane Bancel) signed a memorandum of understanding (MOU) for messenger RNA (mRNA) vaccine research cooperation on the 22nd (local time) at the Willard InterContinental Hotel in Washington DC, USA.

Through this MOU, the National Institute of Health and Moderna expressed mutual interest in promoting scientific research cooperation, including collaborative research on mRNA vaccines in areas of common interest.

The areas of cooperation between the two parties include mRNA vaccines for COVID-19 and its variants, as well as preclinical and clinical research on infectious diseases that potentially have high medical demand and disease burden in Korea.

In the future, detailed research cooperation topics will be decided through specific consultations with Moderna regarding vaccines needed domestically.

Director Kwon Jun-wook of the National Institute of Health said, "We will strengthen cooperation with Moderna and play a leading role in the domestic mRNA vaccine research field. By concretizing the cooperative projects based on this MOU and striving to realize them, we expect to contribute significantly to the development of mRNA vaccines for various diseases needed in Korea beyond just COVID-19 vaccines."

Jang Hee-chang, Director of the National Institute of Infectious Diseases under the National Institute of Health, added, "Through provisional cooperation with Moderna, we hope that the mRNA vaccine research capabilities of the National Institute of Infectious Diseases will be enhanced and that collaborative mRNA research programs will also expand."

This content was produced with the assistance of AI translation services.